Literature DB >> 21698538

[A comprehensive assessment of ATMP. Difficulties and approaches].

M Thanner1, E Nagel.   

Abstract

Advanced therapy medicinal products (ATMP) are associated with high expectations because they offer new opportunities for the treatment of diseases, e.g., the possibility of regenerating damaged or lost tissue. What the products (gene therapy, somatic cell therapy, and tissue engineered products) have in common is an innovative and complex development process that combines science and engineering. At the same time, this field of research is becoming increasingly interdisciplinary and requires international cooperation. A comprehensive assessment of ATMP has to take these issues into account. The application of Beauchamp and Childress' Four Principles (Principle-Based Ethics) as well as Discourse Ethics as a framework may lead to a broader consideration of medical ethics issues.

Mesh:

Substances:

Year:  2011        PMID: 21698538     DOI: 10.1007/s00103-011-1300-7

Source DB:  PubMed          Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz        ISSN: 1436-9990            Impact factor:   1.513


  2 in total

1.  Safety and efficacy of matrix-associated autologous chondrocyte implantation with spheroid technology is independent of spheroid dose after 4 years.

Authors:  Philipp Niemeyer; Volker Laute; Wolfgang Zinser; Thilo John; Christoph Becher; Peter Diehl; Thomas Kolombe; Jakob Fay; Rainer Siebold; Stefan Fickert
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2020-01-02       Impact factor: 4.342

2.  Advanced therapy medicinal products: current and future perspectives.

Authors:  Eve Hanna; Cécile Rémuzat; Pascal Auquier; Mondher Toumi
Journal:  J Mark Access Health Policy       Date:  2016-04-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.